Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11, 2025. The company, which develops Microcyn® technology based stabilized hypochlorous acid (HOCl) products, will showcase its prescription and OTC dermatology products at booth 1054.
The AAD annual meeting is a major dermatology conference featuring over 350 exhibitors, nearly 20,000 attendees including 10,000+ medical personnel, and more than 300 educational sessions. Sonoma aims to expand its distributor network and present its portfolio of products for skin care, scar management, and atopic dermatitis.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha annunciato la sua partecipazione al 2025 American Academy of Dermatology (AAD) Annual Meeting che si svolgerà a Orlando, Florida, dal 7 all'11 marzo 2025. L'azienda, che sviluppa prodotti a base di tecnologia Microcyn® stabilizzata con acido ipocloroso (HOCl), presenterà i suoi prodotti dermatologici da prescrizione e da banco allo stand 1054.
La riunione annuale dell'AAD è una conferenza di dermatologia di grande importanza che ospita oltre 350 espositori, quasi 20.000 partecipanti, tra cui oltre 10.000 operatori sanitari, e più di 300 sessioni educative. Sonoma mira ad ampliare la propria rete di distributori e a presentare il suo portafoglio di prodotti per la cura della pelle, la gestione delle cicatrici e la dermatite atopica.
Sonoma Pharmaceuticals (NASDAQ:SNOA) anunció su participación en la Reunión Anual de la Academia Americana de Dermatología (AAD) 2025 en Orlando, Florida, del 7 al 11 de marzo de 2025. La empresa, que desarrolla productos basados en la tecnología Microcyn® con ácido hipocloroso (HOCl) estabilizado, exhibirá sus productos dermatológicos de prescripción y de venta libre en el stand 1054.
La reunión anual de la AAD es una importante conferencia de dermatología que cuenta con más de 350 expositores, casi 20,000 asistentes, incluidos más de 10,000 profesionales médicos, y más de 300 sesiones educativas. Sonoma tiene como objetivo expandir su red de distribuidores y presentar su cartera de productos para el cuidado de la piel, el manejo de cicatrices y la dermatitis atópica.
소노마 제약 (NASDAQ:SNOA)는 2025년 3월 7일부터 11일까지 플로리다주 올랜도에서 열리는 2025 미국 피부과 아카데미(AAD) 연례 회의에 참여한다고 발표했습니다. 이 회사는 Microcyn® 기술을 기반으로 한 안정화된 차아염소산(HOCl) 제품을 개발하며, 처방 및 일반 판매 피부과 제품을 부스 1054에서 선보일 예정입니다.
AAD 연례 회의는 350개 이상의 전시업체와 거의 20,000명의 참석자, 10,000명 이상의 의료 인력을 포함하며, 300개 이상의 교육 세션이 진행되는 주요 피부과 회의입니다. 소노마는 유통망을 확장하고 피부 관리, 흉터 관리 및 아토피성 피부염을 위한 제품 포트폴리오를 선보일 계획입니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) a annoncé sa participation à la Réunion Annuelle de l'Académie Américaine de Dermatologie (AAD) 2025 qui se tiendra à Orlando, en Floride, du 7 au 11 mars 2025. L'entreprise, qui développe des produits à base de technologie Microcyn® stabilisée avec de l'acide hypochloreux (HOCl), présentera ses produits dermatologiques sur ordonnance et en vente libre au stand 1054.
La réunion annuelle de l'AAD est une conférence dermatologique majeure avec plus de 350 exposants, près de 20 000 participants, dont plus de 10 000 professionnels de santé, et plus de 300 sessions éducatives. Sonoma vise à élargir son réseau de distributeurs et à présenter son portefeuille de produits pour les soins de la peau, la gestion des cicatrices et la dermatite atopique.
Sonoma Pharmaceuticals (NASDAQ:SNOA) gab bekannt, dass sie an der 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, vom 7. bis 11. März 2025 teilnehmen wird. Das Unternehmen, das Produkte auf Basis der stabilisierten Hypochlorigen Säure (HOCl) mit Microcyn®-Technologie entwickelt, wird seine verschreibungspflichtigen und rezeptfreien dermatologischen Produkte am Stand 1054 präsentieren.
Die AAD-Jahrestagung ist eine bedeutende dermatologische Konferenz mit über 350 Ausstellern, fast 20.000 Teilnehmern, darunter mehr als 10.000 medizinisches Personal, und mehr als 300 Bildungsangeboten. Sonoma strebt an, sein Vertriebsnetz auszubauen und sein Produktportfolio für Hautpflege, Narbenmanagement und atopische Dermatitis vorzustellen.
- None.
- None.
BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, March 7-11, 2025.
The AAD annual meeting is one of the leading dermatology conferences in the U.S., with over 350 exhibitors and close to 20,000 attendees, including more than 10,000 medical personnel, and more than 300 educational sessions. Founded in 1938 and headquartered in Rosemont, Illinois, AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails, advocating high standards in clinical practice, education, and research in dermatology, and supporting and enhancing patient care for a lifetime of healthier skin, hair, and nails. Its annual meeting provides an ideal opportunity to connect with peers and industry leaders while learning about the latest advancements in dermatology.
Sonoma Pharmaceuticals is aiming to expand its distributor network and to showcase its line of prescription and OTC dermatology products. Interested parties are invited to visit Sonoma Pharmaceuticals' booth 1054to learn about its patented, innovative, safe, and effective products for skin care, scar management and atopic dermatitis. For more information, please visit https://sonomapharma.com.
"We are excited to attend AAD again this year and to present our portfolio of dermatology products at this highly regarded event," said Amy Trombly, CEO of Sonoma. "We look forward to bridging new connections for the continued distribution of our products and the increased availability of our safe and effective technology in the U.S."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When and where is Sonoma Pharmaceuticals (SNOA) exhibiting at the AAD Annual Meeting 2025?
What products will SNOA showcase at the 2025 AAD Annual Meeting?
How many attendees are expected at the 2025 AAD Annual Meeting where SNOA is exhibiting?
What is the main purpose of SNOA's participation in the 2025 AAD Meeting?
